Education
About Us
Working with TipRanks
Follow Us
Synergy CHC (SNYR)
NASDAQ:SNYR
Top Page
Synergy CHC
(NASDAQ:SNYR)
47Neutral
Synergy CHC (SNYR) vs. S&P 500 (SPY)
Market Cap
$22.54M
Dividend YieldN/A
Average Volume (3M)17.31K
Price to Earnings (P/E)1.4
Beta (1Y)0.27
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees25
SectorConsumer Defensive
Sector Strength91
IndustryMedical - Distribution
Share Statistics
EPS (TTM)1.82
Shares Outstanding8,752,178
10 Day Avg. Volume19,064
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.19
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside295.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Synergy CHC Business Overview & Revenue Model
Company DescriptionSynergy CHC Corp (SNYR) is a consumer healthcare company that specializes in the acquisition, development, and marketing of consumer-branded health and wellness products. The company's portfolio spans various sectors including health, beauty, and medical products, catering to a wide range of consumer needs. Synergy CHC is committed to enhancing the quality of life for its customers through innovative and effective solutions.
How the Company Makes MoneySynergy CHC Corp generates revenue primarily through the sale of its consumer healthcare products. The company employs a multi-channel distribution strategy, leveraging both traditional retail outlets and e-commerce platforms to reach a broad customer base. Key revenue streams include direct sales to consumers through online platforms, as well as partnerships with major retailers. The company's earnings are significantly influenced by its strategic marketing initiatives and product innovation, which drive consumer demand and brand loyalty. Additionally, Synergy CHC may engage in licensing agreements and collaborations with other companies to expand its product offerings and market reach.
Synergy CHC Financial Statement Overview
Summary
Synergy CHC shows revenue and profitability improvements, with a positive gross profit margin. However, the company faces challenges with high leverage and negative equity on its balance sheet. Cash flow trends are positive but need continued improvement to ensure stability.Income Statement
Synergy CHC has demonstrated significant revenue growth, with a 11.37% increase from 2022 to 2023. The gross profit margin improved to 74.96% in 2023 from 34.61% in 2022, indicating enhanced cost management. However, the net profit margin turned positive to 14.81% in 2023 from a negative margin in 2022, highlighting a recovery but still facing challenges in achieving consistent profitability.65
Positive
Balance Sheet
The balance sheet shows high leverage with a negative stockholders' equity of -$27.31 million, resulting in a concerning debt-to-equity ratio and negative equity ratio. Despite improvements, the financial stability remains a concern with the company operating at a deficit in equity.40
Negative
Cash Flow
The transition to positive free cash flow in 2023 is a positive sign, indicating improved cash management. However, the Operating Cash Flow to Net Income ratio is low at 0.07, suggesting challenges in converting profits into cash.55
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 16.54M | 42.78M | 38.41M | 0.00 | 40.23M | 29.36M | Gross Profit |
| 11.57M | 32.08M | 13.30M | 0.00 | 25.55M | 20.22M | EBIT |
| 2.86M | 10.81M | -24.97M | 0.00 | 3.09M | 1.91M | EBITDA |
| 3.17M | 10.84M | -24.63M | 0.00 | 3.19M | -6.88M | Net Income Common Stockholders |
| 1.36M | 6.34M | -32.63M | 0.00 | 1.41M | -9.21M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 27.41K | 632.53K | 1.93M | 0.00 | 1.67M | 1.22M | Total Assets |
| 27.41K | 12.24M | 18.54M | 0.00 | 12.59M | 5.19M | Total Debt |
| 20.69K | 27.63M | 22.83M | 0.00 | 8.75M | 5.71M | Net Debt |
| -6.72K | 26.99M | 20.90M | 0.00 | 7.08M | 4.49M | Total Liabilities |
| 23.69K | 39.55M | 52.06M | 0.00 | 16.27M | 10.39M | Stockholders Equity |
| 3.72K | -27.31M | -33.52M | 0.00 | -3.68M | -5.20M |
| Cash Flow | Free Cash Flow | ||||
| -1.38M | 421.73K | -8.43M | 0.00 | -1.59M | 2.95M | Operating Cash Flow |
| -1.38M | 421.73K | -8.43M | 0.00 | -1.59M | 2.95M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | ― | 0.00 | Financing Cash Flow |
| 895.97K | -2.09M | 8.96M | 0.00 | 1.95M | -2.05M |
Synergy CHC Technical Analysis
Negative
2.53
Price Trends
3.51
Negative
4.37
Negative
3.41
Negative
Market Momentum
-0.24
Positive
29.93
Positive
34.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNYR, the sentiment is Negative. The current price of 2.53 is below the 20-day moving average (MA) of 3.13, below the 50-day MA of 3.51, and below the 200-day MA of 3.41, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 29.93 is Positive, neither overbought nor oversold. The STOCH value of 34.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNYR.
Synergy CHC Peers Comparison
Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $399.94B | 27.17 | 31.05% | 2.33% | 0.49% | 5.02% | |
73 Outperform | $1.06B | 9.32 | 7.19% | ― | -4.36% | -26.64% | |
63 Neutral | $20.94B | 14.39 | -10.05% | 3.13% | 1.25% | 3.11% | |
57 Neutral | $4.81B | 40.12 | 0.33% | ― | 1.35% | -99.94% | |
50 Neutral | $24.41B | 147.29 | -14.17% | 3.47% | 0.07% | -249.21% | |
47 Neutral | $22.54M | 1.39 | -23.21% | ― | ― | ― | |
47 Neutral | $2.02B | ― | -43.06% | ― | -29.44% | -1343.00% |
* Consumer Defensive Sector Average
Performance Comparison
SNYR
Synergy CHC
2.22
2.10
1750.00%
EL
The Estée Lauder Companies
58.19
-82.93
-58.77%
HBI
Hanesbrands
4.92
-0.05
-1.01%
HELE
Helen Of Troy
46.28
-61.52
-57.07%
PG
Procter & Gamble
172.39
20.68
13.63%
COTY
Coty
5.21
-5.85
-52.89%
Synergy CHC Earnings Call Summary
Earnings Call Date: Mar 31, 2025 | % Change Since: -12.76% | Next Earnings Date: Nov 13, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a challenging quarter primarily due to a strategic rebranding and de-inventorying process that impacted revenues. However, the company achieved significant milestones, including a successful IPO and expansion into new retail channels, indicating potential for future growth.Highlights
Successful IPO Completion
Synergy completed its IPO in late October, raising approximately $6.2 million in net proceeds and began trading on the Nasdaq under the symbol SNYR.
Seven Consecutive Quarters of Profitability
Synergy reported its seventh consecutive quarter of profitable results, marking continued financial stability.
Expansion into New Retail Channels
Synergy expanded its retail relationships with BJ's Wholesale Clubs and Publix, increasing distribution points across key markets.
Global Trademark Strategy
Synergy registered 22 FOCUSfactor trademarks globally, paving the way for future growth and sustained market leadership.
Lowlights
Significant Revenue Decline
Revenue in the third quarter was $7.1 million compared to $10.8 million in the year-ago quarter, a decrease of 34%, primarily due to rebranding and retailer de-inventorying.
Gross Margin Reduction
Gross margin in the third quarter decreased 476 basis points to 67.2% compared to 72% a year ago, due to product mix sold within the quarter.
Flat Tummy Brand Revenue Decline
Flat Tummy brand revenue was not up year-over-year, following a sell-through of previous products and prior to the launch of new SKUs.
CFO Departure
CFO Stacy Bieber announced her departure to pursue new opportunities, with Jaime Fickett stepping in as Interim CFO.
Company Guidance
During Synergy CHC Corporation's Q3 2024 earnings call, several key metrics and strategic initiatives were discussed. The company reported a revenue decline to $7.1 million, down from $10.8 million in Q3 2023, attributed primarily to a rebranding effort for their FOCUSfactor products, which led to a temporary $3 million sales impact due to retailer de-inventorying. Despite this, the company maintained a gross margin of 67.2%. EBITDA was reported at $1.3 million, marking a 38% decrease from the previous year. Synergy also highlighted its strategic expansion, noting new retail partnerships, including placement in all 267 BJ's Wholesale Clubs and all 1,200 Publix grocery stores. The company is poised for future growth with plans to introduce new product SKUs and expand its ready-to-drink beverage line in early 2025. The recent IPO, which raised $6.2 million in net proceeds, allowed Synergy to reduce its debt by $3.1 million, strengthening its financial position.Synergy CHC Corporate Events
Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Synergy CHC Appoints New CFO Amidst Leadership Changes
Positive
Mar 31, 2025
On March 27, 2025, Synergy CHC appointed Jaime Fickett as the new Chief Financial Officer, marking a significant leadership change. The company reported its eighth consecutive quarter of profitability for 2024, despite a decrease in revenue and net income due to rebranding efforts and retailer de-inventorying. Synergy successfully completed its initial public offering in October 2024 and expanded its partnerships with major retailers, positioning itself for future growth.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.